Aquestive Therapeutics Inc
NASDAQ:AQST
Aquestive Therapeutics Inc
Cash from Operating Activities
Aquestive Therapeutics Inc
Cash from Operating Activities Peer Comparison
Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
A
|
Aquestive Therapeutics Inc
NASDAQ:AQST
|
Cash from Operating Activities
-$6.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
Johnson & Johnson
NYSE:JNJ
|
Cash from Operating Activities
$22.8B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Cash from Operating Activities
$13.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
18%
|
CAGR 10-Years
15%
|
|
Pfizer Inc
NYSE:PFE
|
Cash from Operating Activities
$8.7B
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
Merck & Co Inc
NYSE:MRK
|
Cash from Operating Activities
$13B
|
CAGR 3-Years
8%
|
CAGR 5-Years
4%
|
CAGR 10-Years
1%
|
|
Eli Lilly and Co
NYSE:LLY
|
Cash from Operating Activities
$4.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
See Also
What is Aquestive Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-6.4m
USD
Based on the financial report for Dec 31, 2023, Aquestive Therapeutics Inc's Cash from Operating Activities amounts to -6.4m USD.
What is Aquestive Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
13%
Over the last year, the Cash from Operating Activities growth was 35%. The average annual Cash from Operating Activities growth rates for Aquestive Therapeutics Inc have been 48% over the past three years , 13% over the past five years .